These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 18808686)

  • 41. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
    Wolff RA; Evans DB; Gravel DM; Lenzi R; Pisters PW; Lee JE; Janjan NA; Charnsangavej C; Abbruzzese JL
    Clin Cancer Res; 2001 Aug; 7(8):2246-53. PubMed ID: 11489798
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
    Roxburgh P; Lumsden GR; Paul J; Harden S; Sweeting L; James A; Crellin A; Morrison R; Evans TR; McDonald AC
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):131-9. PubMed ID: 24819683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
    Aparicio J; García-Mora C; Martín M; Petriz ML; Feliu J; Sánchez-Santos ME; Ayuso JR; Fuster D; Conill C; Maurel J
    PLoS One; 2014; 9(1):e82209. PubMed ID: 24416138
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advanced Pancreatic Cancer (RECLAP) study.
    Beane JD; Griffin KF; Levy EB; Pandalai P; Wood B; Abi-Jaoudeh N; Beresnev T; Shutack Y; Webb CC; Avital I; Rudloff U
    Invest New Drugs; 2015 Feb; 33(1):109-18. PubMed ID: 25236592
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: a phase I trial.
    Lin Q; Liu YE; Ren XC; Wang N; Chen XJ; Wang DY; Zong J; Peng Y; Guo ZJ; Hu J
    Radiat Oncol; 2013 Aug; 8(1):201. PubMed ID: 23957889
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
    De Santis M; Bachner M; Cerveny M; Kametriser G; Steininger T; Königsberg R; Schratter-Sehn A; Sedlmayer F; Dittrich C
    Ann Oncol; 2014 Sep; 25(9):1789-1794. PubMed ID: 24936582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
    Pipas JM; Barth RJ; Zaki B; Tsapakos MJ; Suriawinata AA; Bettmann MA; Cates JM; Ripple GH; Sutton JE; Gordon SR; McDonnell CE; Perez RP; Redfield N; Meyer LP; Marshall JF; Cole BF; Colacchio TA
    Ann Surg Oncol; 2005 Dec; 12(12):995-1004. PubMed ID: 16252135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
    Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
    Crane CH; Janjan NA; Evans DB; Wolff RA; Ballo MT; Milas L; Mason K; Charnsangavej C; Pisters PW; Lee JE; Lenzi R; Vauthey JN; Wong A; Phan T; Nguyen Q; Abbruzzese JL
    Int J Pancreatol; 2001; 29(1):9-18. PubMed ID: 11560155
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
    Gagel B; Piroth M; Pinkawa M; Reinartz P; Krohn T; Kaiser HJ; Stanzel S; Breuer C; Asadpour B; Schmachtenberg A; Eble MJ
    BMC Cancer; 2007 Jun; 7():112. PubMed ID: 17598906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
    Rakhra S; Strauss JB; Robertson J; McGinn CJ; Kim T; Huang J; Blake A; Helenowski I; Hayes JP; Mulcahy M; Small W
    J Gastrointest Cancer; 2016 Jun; 47(2):196-201. PubMed ID: 27112332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
    Ben-Josef E; Schipper M; Francis IR; Hadley S; Ten-Haken R; Lawrence T; Normolle D; Simeone DM; Sonnenday C; Abrams R; Leslie W; Khan G; Zalupski MM
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1166-71. PubMed ID: 22543215
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    Regine WF; Winter KA; Abrams RA; Safran H; Hoffman JP; Konski A; Benson AB; Macdonald JS; Kudrimoti MR; Fromm ML; Haddock MG; Schaefer P; Willett CG; Rich TA
    JAMA; 2008 Mar; 299(9):1019-26. PubMed ID: 18319412
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.
    Blackstock AW; Bernard SA; Richards F; Eagle KS; Case LD; Poole ME; Savage PD; Tepper JE
    J Clin Oncol; 1999 Jul; 17(7):2208-12. PubMed ID: 10561277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
    Brunner TB; Grabenbauer GG; Klein P; Baum U; Papadopoulos T; Bautz W; Hohenberger W; Sauer R
    Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):144-53. PubMed ID: 12504047
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
    Epelbaum R; Rosenblatt E; Nasrallah S; Faraggi D; Gaitini D; Mizrahi S; Kuten A
    J Surg Oncol; 2002 Nov; 81(3):138-43. PubMed ID: 12407726
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase I study of combination of intravenous gemcitabine, oxaliplatin, and 5-FU with daily oral thalidomide (GOFT) in metastatic/locally advanced pancreatic carcinoma patients.
    Shan YS; Lin PW
    Hepatogastroenterology; 2007; 54(79):2141-5. PubMed ID: 18251177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.